<DOC>
	<DOCNO>NCT00677170</DOCNO>
	<brief_summary>This study open-label , multicenter , Phase 1 , dose escalation study MLN4924 adult patient nonhematologic malignancy . This study first administer MLN4924 human . The patient population consist adult form nonhematologic malignancy standard , curative , life prolonging , palliative treatment exist longer effective .</brief_summary>
	<brief_title>Study MLN4924 Adult Patients With Nonhematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Male female patient 18 year old Eastern Cooperative Oncology Group performance status 02 Patients must diagnosis nonhematologic malignancy standard curative , lifeprolonging , palliative treatment exist longer effective . Expected survival longer 6 week enrollment study Radiographically clinically evaluable tumor Suitable venous access conduct blood sample MLN4924 Tumor tissue , opinion investigator , safely biopsied use core needle Male patient must use appropriate method barrier contraception Female patient must postmenopausal , surgically sterilize , willing use reliable method birth control Voluntary write consent Pregnant lactate Major surgery within 14 day prior first dose study treatment Serious infection within 14 day prior first dose study treatment Receiving antibiotic therapy within 14 day prior first dose study treatment Lifethreatening illness unrelated cancer Diarrhea great Grade 1 severity Systemic antineoplastic therapy within 21 day precede first dose study treatment Radiotherapy within 21 day precede first dose study treatment Prior treatment radiation therapy involve â‰¥25 % hematopoietically active bone marrow CYP3A inducer within 14 day first dose MLN4924 . Moderate strong CYP3A inhibitor CYP3A inducer permit study . Clinically significant central nervous system metastases Absolute neutrophil count &lt; 1,500/mm3 ; platelet count &lt; 100,000/mm3 Patients prothrombin time aPTT &gt; 1.5 x upper limit normal range , history coagulopathy bleed disorder Ongoing anticoagulant therapy hold permit tumor biopsy Calculated creatinine clearance &lt; 50 mL/minute Bilirubin &gt; 1.5 time upper limit normal ; aspartate aminotransferase , alanine aminotransferase , alkaline phosphatase &gt; 2.5 time upper limit normal . Uncontrolled cardiovascular condition , include cardiac arrhythmia , congestive heart failure , angina , myocardial infarction within past 6 month Abnormalities 12lead electrocardiogram include , limited , change rhythm interval opinion investigator consider clinically significant Known human immunodeficiency virus positive hepatitis B surface antigenpositive status , know suspect active hepatitis C infection Treatment investigational product within 28 day precede first dose study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>